1. Home
  2. BTMD vs CING Comparison

BTMD vs CING Comparison

Compare BTMD & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biote Corp.

BTMD

Biote Corp.

HOLD

Current Price

$2.17

Market Cap

72.7M

Sector

Health Care

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.19

Market Cap

64.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTMD
CING
Founded
2012
2012
Country
United States
United States
Employees
N/A
14
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.7M
64.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BTMD
CING
Price
$2.17
$5.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$2.83
$34.50
AVG Volume (30 Days)
199.3K
437.2K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
722.22
N/A
EPS
0.74
N/A
Revenue
$192,219,000.00
N/A
Revenue This Year
$2.03
N/A
Revenue Next Year
$6.58
N/A
P/E Ratio
$2.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$3.20
52 Week High
$4.75
$11.89

Technical Indicators

Market Signals
Indicator
BTMD
CING
Relative Strength Index (RSI) 58.16 43.71
Support Level $2.02 $4.94
Resistance Level $2.20 $6.79
Average True Range (ATR) 0.12 0.48
MACD -0.02 0.05
Stochastic Oscillator 54.15 40.42

Price Performance

Historical Comparison
BTMD
CING

About BTMD Biote Corp.

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: